Advertisement
OtherDRUG METABOLISM AND DISPOSITION

Multispecific Organic Anion Transporter Is Responsible for the Biliary Excretion of the Camptothecin Derivative Irinotecan and its Metabolites in Rats

Xiao-Yan Chu, Yukio Kato, Kayoko Niinuma, Ken-Ichi Sudo, Hideo Hakusui and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics April 1997, 281 (1) 304-314;

Abstract

Irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11), is a potent anticancer drug that is increasingly used in chemotherapy. A frequent limiting side effect involves gastrointestinal toxicity (diarrhea), which is thought to be related to the biliary excretion of CPT-11 and its metabolites. Accordingly, the biliary excretion mechanisms for both the lactone and carboxylate forms of CPT-11 and its metabolites, SN-38 and its glucuronide (SN38-Glu), were investigated using Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rats (EHBR), with the latter being mutant rats with a genetic deficiency of the canalicular multispecific organic anion transporter. After i.v. administration of CPT-11, the biliary excretion clearance, defined as the biliary excretion rate normalized to the hepatic concentration, of both the lactone and carboxylate forms of SN38-Glu was much lower in EHBR. The biliary excretion clearance for the carboxylate form of both CPT-11 and SN-38 was also substantially smaller in EHBR and showed marked saturation with increasing dose only in SD rats. On the other hand, the biliary excretion clearance for the lactone forms of CPT-11 and SN-38 showed only a minimal difference in EHBR, compared with SD rats. These results suggest that, for the carboxylate form of CPT-11 and SN-38 and the carboxylate and lactone forms of SN38-Glu, there exists a specific transport system at the bile canalicular membrane that is deficient in EHBR. To confirm this hypothesis, the uptake of these substrates by isolated hepatic canalicular membrane vesicles (CMV) was examined. ATP-dependence was clearly observed for the uptake of these four compounds by CMV prepared from SD rats but not by CMV from EHBR. In addition, the compounds inhibited the ATP-dependent uptake ofS-(2,4-dinitrophenyl) glutathione by CMV from SD rats, in a concentration-dependent manner. These results suggest that the biliary excretion of the carboxylate forms of CPT-11 and SN-38 and the carboxylate and lactone forms of SN38-Glu is mediated by the multispecific organic anion transporter, which is deficient in EHBR.

CPT, a plant alkaloid isolated from a tree found in China (Camptotheca accuminata), is a novel antitumor agent that exerts its activity exclusively by inhibition of topoisomerase I (Kim et al., 1992; Slichenmyeret al., 1993; Tanizawa et al., 1994). However, clinical evaluation of CPT was discontinued due to its unpredictably severe toxicity and poor water-solubility. Recently, several semisynthetic analogs of CPT have been developed (Miyasaka et al., 1981; Nagata, et al., 1987). Irinotecan (CPT-11) is a water-soluble analog of CPT that was discovered in an attempt to identify derivatives with greater water-solubility and antitumor activity than CPT (Hertzberg et al., 1989). CPT-11 acts as a prodrug that undergoes deesterification in vivo to yield SN-38, a metabolite that is 1000-fold more potent than the parent compound in vitro (Kawato et al., 1991; Kojimaet al., 1993).

CPT-11 shows potent anticancer activity in many types of human tumor cells, including small-cell and non-small-cell lung cancers, malignant lymphoma, cervical cancer, ovarian cancer and colorectal cancer (Ohnoet al., 1990; Negoro et al., 1991; Sasakiet al., 1995a). It has undergone phase I and II clinical trials in several countries. The major toxic effects of CPT-11 are myelosuppression and gastrointestinal toxicity, especially unpredictable, severe diarrhea (Araki et al., 1993). Such intestinal toxicity, however, exhibits large interpatient variability (Rothenberg et al., 1993; Rowinsky et al., 1994;Sasaki et al., 1995b), the mechanisms for which are currently unknown. One postulated mechanism for the toxicity of CPT-11 is related to the biliary excretion of its metabolites. After the administration of CPT-11, the active metabolite SN-38 is formed by deesterification. SN-38 is further conjugated to SN38-Glu in the liver and mainly excreted via the bile duct, followed by deconjugation by intestinal microflora to regenerate SN-38, which may cause diarrhea (Kaneda et al., 1990). However, the biliary excretion mechanism of CPT-11 and its metabolites has not been identified.

CPT-11 and its metabolites have an α-hydroxy-δ-lactone ring, which undergoes reversible hydrolysis at a rate that depends on many factors, including pH, ionic strength and protein concentration (Fassberg and Stella, 1992; Burke and Mi, 1994; Rivory and Robert, 1994) (fig.1). The lactone form is essential for the activity of SN-38, and the lactone-hydrolyzed form (carboxylate form) exhibits only minimal topoisomerase I-inhibitory activity (Slichenmyer et al., 1993). At physiological pH, however, the lactone form is unstable and the equilibrium favors hydrolysis to open the lactone ring and yield the carboxylate form. Under acidic conditions, the reverse reaction, with formation of the lactone, is favored. Similar reactions also occur with CPT-11 and SN38-Glu (fig. 1). Among these six compounds, anionic charges are present on the carboxylate forms of CPT-11 and SN-38 and the carboxylate and lactone forms of SN38-Glu. Recently, it has been proposed that the hepatic cMOAT, which is expressed on the bile canalicular membrane, transports several types of organic anions into the bile as a primary active transport system (Ishikawa et al., 1990; Nishida et al., 1992;Sathirakul et al., 1993, 1994; Shimamura et al., 1994; Pikula et al., 1994; Yamazaki et al., 1996). Therefore, the four CPT-11-related compounds with an anionic charge may be recognized by the cMOAT. In this study, the biliary excretion mechanisms of both the carboxylate and lactone forms of CPT-11 and its metabolites were investigated in rats. EHBR derived from SD rats were used for this purpose; EHBR are genetically deficient with respect to cMOAT on the bile canalicular membrane (Fernandez-Checaet al., 1992; Takenaka et al., 1995a). The biliary excretion of CPT-11 and its metabolites was compared in SD rats and EHBR in vivo. The isolated bile CMV from SD rats and EHBR were also used for the transport study of CPT-11 and its metabolites.

Figure 1
Figure 1

Chemical structures of the lactone and carboxylate forms of CPT-11 and its metabolites SN-38 and SN38-Glu.

Materials and Methods

Materials

CPT-11, SN-38 and SN38-Glu were obtained from Daiichi Pharmaceutical Co. Ltd. (Tokyo, Japan) and the Yakult Honsha Co. Ltd. (Tokyo, Japan). The lactone and carboxylate forms of CPT-11, SN-38 and SN38-Glu were produced by dissolving the compounds in 50 mM phosphate buffer at pH 3.0 or 9.0 and leaving them overnight. The conversion of the lactones into carboxylates or carboxylates into lactones was virtually complete (>99%), as determined by HPLC. CPT, as an internal standard, was obtained from Sigma Chemical Co. (St. Louis, MO). [3H]DNP-SG (50.0 μCi/nmol) was synthesized according to the method described previously (Kobayashi et al., 1990). All other chemicals were commercial products and of analytical grade. Male SD rats weighing 250 to 300 g were purchased from Nisseizai (Tokyo, Japan), and male EHBR weighing 250 to 300 g were supplied by Eisai Laboratories (Gifu, Japan).

In Vivo Study

The SD rats and EHBR underwent cannulation of the femoral vein and artery using PE50 polyethylene tubing (inner diameter, 0.58 mm; outer diameter, 0.965 mm; Becton Dickinson & Co., Parsippany, NJ), and the bile duct was cannulated with PE10 polyethylene tubing (inner diameter, 0.28 mm; outer diameter, 0.61 mm; Becton Dickinson) under light anesthesia with ether. After the operation, the rats were kept in Bollman cages, with free access to food and water. The temperatures of the rats were monitored and found to remain constant during the experiment. CPT-11 was dissolved in distilled water with sonication and then diluted with 9% NaCl to give a final NaCl concentration of 0.9%. After i.v. injection of 10 or 40 mg/kg levels of the lactone form of CPT-11 (1 ml/250 g b.wt.), approximately 0.5 ml of blood was collected at 5 min, 30 min, 2 hr, 4 hr and 8 hr, transferred to centrifuge tubes containing 5 μl of 10 mM diisopropyl fluorophosphate dissolved in dimethylsulfoxide, kept on ice during the sampling period and finally centrifuged at 4°C. The plasma (0.2 ml) obtained was frozen under liquid N2 immediately after harvesting. Bile samples were collected at 0 to 1, 1 to 2, 2 to 4, 4 to 6 and 6 to 8 hr; urine samples were collected spontaneously. To avoid conversion of the lactone and carboxylate forms of CPT-11 and its metabolites during sampling, bile and urine samples were collected every 2 hr, kept on ice during sampling and frozen immediately in liquid N2 when sampling was complete. At 8 hr, the rats were sacrificed, and the livers were removed and immediately frozen in liquid N2. Concentrations of both the lactone and carboxylate forms of CPT-11 and its metabolites were determined by HPLC, as described below. The urine samples obtained up to 8 hr were combined, and the total volume was determined before HPLC determination.

In Vitro Uptake by CMV

CMV were prepared from male SD rats and EHBR as described previously (Kobayashi et al., 1990). The CMV were resuspended in 250 mM sucrose containing 50 mM Tris-HCl (pH 7.4), frozen in liquid N2 and stored at −100°C until use. The purity of the prepared CMV was evaluated by determining the activities of Mg++-ATPase and alkaline phosphatase, according to the methods of Scharschmidt et al. (1979) and Yachi et al. (1989), respectively. The activity of prepared CMV was also checked by measuring the ATP-dependent uptake of standard substrates, [3H]taurocholate (1 μM) and [3H]DNP-SG (1 μM; 0.1 μM labeled and 0.9 μM unlabeled), at 37°C for 2 min.

Uptake of the carboxylate and lactone forms of CPT-11 and its metabolites.

The incubation medium for the uptake studies contained 0.25 M sucrose, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 5 mM ATP, 10 mM creatine phosphate and 100 μg/ml creatine phosphokinase. Control experiments were performed without the addition of ATP. The uptake study was performed at 37°C. After preincubation for 2 min, 5 μl of the carboxylate or lactone form of CPT-11 or its metabolites, which had been diluted with incubation medium to give a final pH of 7.4, was added to give a final ligand concentration of 50 μM. After preincubation for an additional 1 min, uptake was started by the addition of vesicles to give a final protein concentration of 1 mg/ml; the final incubation volume was 20 μl. At designated times, transport was terminated by addition of 1 ml of ice-cold stop solution, followed immediately by filtration through premoistened 0.45-μm HA Millipore filters (catalog no. HAWP 02500; Millipore Corp., Bedford, MA), which were subsequently washed twice with an additional 5.0 ml of ice-cold stop solution. The stop solution contained 10 mM Tris-HCl (pH 7.4), 0.25 M sucrose and 0.1 M NaCl. Filters were dried, cut into small pieces and frozen immediately under liquid N2 for HPLC analysis. The nonspecific binding of drugs to the filters was also determined without CMV, and values for the CMV uptake were obtained by subtracting this nonspecific binding from the apparent uptake. Such nonspecific binding to the filter, normalized by the protein amount in the equivalent volume of incubation mixture with CMV, was 927 ± 57 and 893 ± 50 pmol/mg protein for the lactone form of CPT-11 in the presence and absence of ATP; 582 ± 9 and 554 ± 35 pmol/mg protein for the carboxylate form of CPT-11 in the presence and absence of ATP; 10.8 ± 5.5 and 9.09 ± 3.63 pmol/mg protein for the carboxylate form of SN-38 in the presence and absence of ATP; 19.5 ± 2.8 and 22.1 ± 0.7 pmol/mg protein for the lactone form of SN38-Glu in the presence and absence of ATP; 11.7 ± 0.9 and 12.4 ± 1.4 pmol/mg protein for the carboxylate form of SN38-Glu in the presence and absence of ATP; and 2.57 ± 0.55 and 2.47 ± 0.31 pmol/mg protein for [3H]DNP-SG in the presence and absence of ATP.

Effect of the lactone and carboxylate forms of CPT-11 and its metabolites on the uptake of [3H]DNP-SG.

For transport studies involving the effect of the lactone and carboxylate forms of CPT-11 and its metabolites on the uptake of [3H]DNP-SG, 1.0 μM [3H]DNP-SG was used. After preincubation at 37°C for 2 min, the inhibitor was added and a further preincubation for 1 min was allowed. Inhibitor concentrations used were 0.03, 0.1, 0.3, 1, 10 and 500 μM for the lactone and carboxylate forms of SN38-Glu; 1, 50 and 500 μM for the lactone form of CPT-11; 0.3, 1, 10, 30, 50 and 500 μM for the carboxylate form of CPT-11; and 1, 10, 30, 50 and 500 μM for the carboxylate form of SN-38. After preincubation, the CMV obtained from SD rats was added to give a final protein concentration of 0.5 mg/ml. The final incubation volume was 20 μl. After incubation for 2 min, the reaction was terminated as described above. Radioactivity retained on the filter was determined using a liquid scintillation counter.

HPLC Analysis

The analysis of the carboxylate and lactone forms of CPT-11 and its metabolites was accomplished by HPLC, as described previously (Rivory and Robert, 1994; Sasaki et al., 1995b), with a modification that permitted the simultaneous determination of CPT-11, SN-38 and SN38-Glu. Briefly, for the analysis of plasma samples, 50 μl of ice-cold 50 mM phosphate buffer (pH 6.0) was added to 200 μl of plasma, followed by the addition of 50 μl of the ice-cold lactone form of CPT, as an internal standard, and 450 μl of methanol. The mixture was vortex-mixed for 10 sec and centrifuged at 4°C for 5 min. Then 70 μl of 50 mM phosphate buffer (pH 6.0) was added to 100 μl of supernatant, and the mixture was injected immediately onto the HPLC column, followed by determination of only the lactone forms, because of large interference peaks around the retention times of the carboxylate forms. Total (sum of lactone and carboxylate forms) drug was determined as the lactone in the same manner, except that 70 μl of 0.3 M HCl was added instead of 50 mM phosphate buffer, to ensure complete lactonization of the drug. The carboxylate form of the drug was determined by subtraction of the lactone form from the total drug concentration. Bile and urine samples were diluted with 50 mM phosphate buffer (pH 6.0), and liver samples (0.5 g) were homogenized with 3 ml of methanol/50 mM phosphate buffer (pH 6.0) (7:3, v/v) for the analysis of the lactone and total concentrations in the same way. Because there were no interfering peaks in the samples from the in vitroCMV uptake study, the lactone and carboxylate forms of the drugs were determined simultaneously by using the method for the lactone form determination described above. In the uptake study, the conversion of the lactone and carboxylate forms of the drug on the filter and in the medium during the experiment was <5%, as determined by HPLC. Therefore, only the total concentration of drugs was determined when analyzing filter and medium samples. Briefly, for the analysis of filter samples, 250 μl of ice-cold 50 mM phosphate buffer (pH 6.0) was added to the filter, followed by 50 μl of the ice-cold lactone form of CPT, as an internal standard, and 450 μl of methanol. The mixture was vortex-mixed for 1.5 min, to extract the drugs on the filter, and was centrifuged at 4°C for 5 min. Then, 70 μl of 0.3 M HCl was added to 100 μl of supernatant, and the mixture (50 μl) was injected onto the HPLC column, followed by determination of only the total form of the drugs. The medium samples were diluted with 50 mM phosphate buffer (pH 6.0) to give a total volume of 250 μl, followed by the addition of 50 μl of the ice-cold lactone form of internal standard and 450 μl of methanol. The mixture was vortex-mixed for 10 sec and centrifuged at 4°C for 5 min. Then, 70 μl of 0.3 M HCl was added to 100 μl of supernatant, and the mixture was injected onto the HPLC column for drug determination.

The HPLC system consisted of an Hitachi L-6300 pump, a Tosoh TSK Gel ODS-80Ts (150 × 4.6 mm inner diameter) column with a TSK Guardgel ODS-80Ts guard column, an Hitachi AS-4000 autosampler and an Hitachi F-1050 fluorescence detector. The excitation and emission settings for the in vivo analysis were 375 and 545 nm, respectively. The limits of detection, in terms of the amount of sample injected onto the HPLC column, were 0.2, 0.03 and 0.4 pmol for the lactone forms of CPT-11, SN-38 and SN38-Glu, respectively. In the CMV uptake study, the excitation and emission settings were 370 and 430 nm for CPT-11 and SN38-Glu and 380 and 556 nm for SN-38, respectively. The limits of detection were 0.0074, 0.01 and 0.0044 pmol for the lactone forms of CPT-11, SN-38 and SN38-Glu, respectively. The operation of the HPLC system was controlled by an Hitachi D-6100 HPLC manager. The mobile phase consisted of solvent A of acetonitrile/tetrahydrofuran/0.9 mM 1-heptanesulfonic acid sodium salt in 50 mM phosphate buffer (pH 6.0) (8:4:88) and solvent B of acetonitrile/5 mM 1-heptanesulfonic acid sodium salt in 50 mM phosphate buffer (pH 6.0) (30:70). The total elution time was 22 min, with 100% solvent A from 0 to 7 min, 100% solvent B from 7.1 to 16 min and 100% solvent A from 16.1 to 22 min. The flow rate was 0.9 ml/min.

Data Analysis

The AUC(0–8hr) for the lactone and carboxylate forms of CPT-11 and its metabolites was calculated by the trapezoidal rule. CL bile,p was calculated from the following equation:CLbile,p=Xbile(0­8hr)/AUC(0–8hr) Equation 1where X bile(0–8hr) is the cumulative amount excreted into bile over 0 to 8 hr.CL bile,h, defined as biliary excretion rate divided by the hepatic concentration of the drug, was calculated from the following equation:CLbile,h=Vbile(8hr)/Xliver(8hr) Equation 2where V bile(8hr) andX liver(8hr) are the biliary excretion rate and hepatic concentration at 8 hr, with dimensions of milligram per minute per kilogram and milligram per gram of liver, respectively.V bile(8hr) was approximated by the following equation:Vbile(8hr)≅Xbile(6–8hr)/120 min Equation 3where X bile(6–8hr) is the amount of drug excreted into the bile duct from 6 to 8 hr. Thus, theCL bile,h calculated has the dimensions of grams of liver per minute per kilogram. It was assumed that 1 g of liver is equivalent to 1 ml and, therefore, theCL bile,h has the dimensions of milliliter per minute per kilogram.

C bile/C liver was calculated from the following equation:Cbile/Cliver=Cbile(8hr)/Xliver(8hr) Equation 4where C bile(8hr) is the drug concentration in bile at 8 hr and approximated by the following equation:Cbile(8hr)≅Cbile(6–8hr)=Vbile(6–8hr)/Qbile(6–8hr) Equation 5where V bile(6–8hr) is the rate of drug excreted into the bile duct from 6 to 8 hr.Q bile(6–8hr) is the bile flow rate from 6 to 8 hr.

The CL r was calculated fromCLr=Xurine(0–8hr)/AUC(0–8hr) Equation 6where X urine(0–8hr) is the cumulative amount excreted into urine from 0 to 8 hr.

The inhibition constant (K i) values for evaluating the inhibitory effect of CPT-11 and its metabolites on the uptake of [3H]DNP-SG by CMV from SD rats were obtained by fitting the following equation to the data:V(+I)/V(−I)=1/1+(I/Ki) Equation 7where V (+I) andV (−I) represent the transport velocity in the presence and absence of inhibitor, respectively; I is the inhibitor concentration. This equation was derived based on the assumption of competitive inhibition and the fact that the [3H]DNP-SG concentration (1 μM) is much lower than theK m value (71 μM) (Akerboom et al., 1991) for DNP-SG uptake.

Statistical Method

The results are shown as means ± S.E. for the number of determinations. Dunnett’s test was used to determine the significance of differences between the means of two groups, with P < .01 and P < .05 as the minimum levels of significance.

Results

Plasma concentration-time profiles of CPT-11 and its metabolites.

The plasma concentration-time profiles for the lactone and carboxylate forms of CPT-11, SN-38 and SN38-Glu after i.v. injection of the lactone form of CPT-11 to SD rats and EHBR are shown in figures 2, 3 and 4, respectively. In the time period immediately after i.v. injection, CPT-11 was mainly present in plasma as the lactone form in both SD rats and EHBR; subsequently, the carboxylate form of CPT-11 appeared gradually in plasma (fig. 2). In SD rats, the AUC(0–8hr)of the lactone form of CPT-11 exhibited nonlinearity with increasing dose, whereas minimal saturation could be observed in EHBR (table1). The plasma concentration of the active metabolite SN-38 was much lower than that of the parent drug CPT-11 (fig. 3). Similarly, with CPT-11, the carboxylate form of SN-38 appeared gradually in plasma with time (fig. 3). At a dose of 10 mg/kg, the disappearance of the carboxylate form of SN-38 in plasma of SD rats was much faster than in EHBR, whereas the difference in the disappearance curve of the carboxylate form of SN-38 was minimal at 40 mg/kg for the SD and EHBR strains (fig. 3). The AUC(0–8hr) for the carboxylate form of SN-38 differed markedly between SD rats and EHBR (0.0474 ± 0.0081 μg·hr/ml and 0.339 ± 0.078 μg·hr/ml for SD rats and EHBR, respectively) at 10 mg/kg but was very similar for the two strains at 40 mg/kg (0.249 ± 0.064 μg·hr/ml and 0.245 ± 0.060 μg·hr/ml for SD rats and EHBR, respectively) (table 2). The plasma disappearance of both the lactone and carboxylate forms of SN38-Glu was also slower in EHBR at 10 mg/kg, compared with that in SD rats (fig. 4). On the other hand, at the higher dose (40 mg/kg), similar concentration-time profiles were obtained for both the carboxylate and lactone forms of SN38-Glu with each strain (fig. 4). The difference in AUC(0–8hr) for both the carboxylate and lactone forms of SN38-Glu between SD rats and EHBR was much more marked at the lower dose (10 mg/kg) than at the higher dose (40 mg/kg) (table3).

Figure 2
Figure 2

Plasma concentration-time curves for the lactone (A and B) and carboxylate (C and D) forms of CPT-11 after i.v. administration of the lactone form of CPT-11 (10 and 40 mg/kg) in SD rats (A and C) and EHBR (B and D) with bile cannulation. Each data point represents the mean ± S.E. of three different rats. ▪, lactone form at 10 mg/kg; □, carboxylate form at 10 mg/kg; •, lactone form at 40 mg/kg; ○, carboxylate form at 40 mg/kg.

Figure 3
Figure 3

Plasma concentration-time curves for the lactone (A and B) and carboxylate (C and D) forms of SN-38 after i.v. administration of the lactone form of CPT-11 (10 and 40 mg/kg) in SD rats (A and C) and EHBR (B and D) with bile cannulation. Each data point represents the mean ± S.E. of three different rats. ▪, lactone form at 10 mg/kg; □, carboxylate form at 10 mg/kg; •, lactone form at 40 mg/kg; ○, carboxylate form at 40 mg/kg.

Figure 4
Figure 4

Plasma concentration-time curves for the lactone (A and B) and carboxylate (C and D) forms of SN38-Glu after i.v. administration of the lactone form of CPT-11 (10 and 40 mg/kg) in SD rats (A and C) and EHBR (B and D) with bile cannulation. Each data point represents the mean ± S.E. of three different rats. ▪, lactone form at 10 mg/kg; □, carboxylate form at 10 mg/kg; •, lactone form at 40 mg/kg; ○, carboxylate form at 40 mg/kg.

View this table:
Table 1

Pharmacokinetic parameters of lactone and carboxylate forms of CPT-11 after i.v. administration of CPT-11 (10 and 40 mg/kg) in SD rats and EHBR

View this table:
Table 2

Pharmacokinetic parameters of lactone and carboxylate forms of SN-38 after i.v. administration of CPT-11 (10 and 40 mg/kg) in SD rats and EHBR

View this table:
Table 3

Pharmacokinetic parameters of lactone and carboxylate forms of SN38-Glu after i.v. administration of CPT-11 (10 and 40 mg/kg) in SD rats and EHBR

Biliary excretion of CPT-11 and its metabolites.

The biliary excretion of CPT-11 and its metabolites was measured up to 8 hr in SD rats and EHBR after i.v. injection of the lactone form of CPT-11 (figs.5 and 6). The bile flow rate was not significantly affected by i.v. injection of CPT-11 in either SD rats or EHBR. The pharmacokinetic parameters obtained are listed in tables 1, 2and 3. For the carboxylate form of CPT-11, with increasing dose, clear saturation of biliary excretion was observed in SD rats, whereas no apparent saturation was found in the EHBR (fig. 5, C and D). As for the lactone form of CPT-11, saturation was also observed but in both SD rats and EHBR (fig. 5, A and B). As shown in figure 6, SN-38 was mainly excreted into bile as the carboxylate form both in SD rats and EHBR. The cumulative amount of the carboxylate form of SN-38 excreted into bile exhibited almost no change even with increasing dose in SD rats (table 2), showing a clear saturation. On the other hand, such nonlinearity was not observed in EHBR (table 2). In SD rats, clear saturation of biliary excretion for both the lactone and carboxylate forms of SN38-Glu was observed with increasing dose (fig. 6). On the other hand, in EHBR, the biliary excretion of the lactone and carboxylate forms of SN38-Glu was not so clear, compared with SD rats (fig. 6).

Figure 5
Figure 5

Biliary excretion of the lactone (A and B) and carboxylate (C and D) forms of CPT-11 after i.v. administration of CPT-11 (10 and 40 mg/kg) in SD rats (A and C) and EHBR (B and D). Each data point represents the mean ± S.E. of three different rats. ▪, lactone form at 10 mg/kg; □, carboxylate form at 10 mg/kg; •, lactone form at 40 mg/kg; ○, carboxylate form at 40 mg/kg.

Figure 6
Figure 6

Biliary excretion of the lactone (A and B) and carboxylate (C and D) forms of SN-38 and SN38-Glu after i.v. administration of the lactone form of CPT-11 (10 and 40 mg/kg) in SD rats (A and C) and EHBR (B and D). Each data point represents the mean ± S.E. of three different rats. ▪, lactone form of SN-38 at 10 mg/kg; □, carboxylate form of SN-38 at 10 mg/kg; •, lactone form of SN-38 at 40 mg/kg; ○, carboxylate form of SN-38 at 40 mg/kg; ♦, lactone form of SN38-Glu at 10 mg/kg; ⋄, carboxylate form of SN38-Glu at 10 mg/kg; ▴, lactone form of SN38-Glu at 40 mg/kg; ▵, carboxylate form of SN38-Glu at 40 mg/kg.

Estimation of CLbile,p andCLbile,h.

TheCL bile,p value of both the lactone and carboxylate forms of CPT-11 exhibited nonlinearity in SD rats. Moreover, the saturation of CL bile,p for the carboxylate form of CPT-11 was more marked than that of the lactone form (table 1). In contrast, no clear saturation could be observed forCL bile,p of the lactone or carboxylate form of CPT-11 in EHBR. The CL bile,h was reduced for the carboxylate form of CPT-11 as the dose increased only in SD rats; no nonlinearity could be observed in EHBR. The reduction inCL bile,h for the lactone form of CPT-11 was minimal with increasing dose in both SD rats and EHBR. The absolute value of the CL bile,h for the carboxylate form of CPT-11 was much larger than that of the lactone form in SD rats, especially at the lower dose (10 mg/kg). In addition, at 10 mg/kg, theCL bile,h of the carboxylate form of CPT-11 in SD rats was larger than that in EHBR; at the higher dose, the difference was smaller (table 1). Similar results were also observed for theCL bile,p and CL bile,h of SN-38 (table 2). A reduction in CL bile,h with increasing dose was not observed for the lactone form of SN-38 but was present for the carboxylate form in SD rats. TheCL bile,h value for the carboxylate form of SN-38 was larger in SD rats than in EHBR, especially at the lower dose. In contrast, no marked difference was found for the lactone form of SN-38 in CL bile,h between SD rats and EHBR (table 2). For SN38-Glu, the CL bile,h value of both the lactone and carboxylate forms was clearly lower in EHBR than in SD rats. In SD rats, the CL bile,h value of the carboxylate form was larger than that of the lactone form at 10 mg/kg, and saturation was more marked for the carboxylate form than for the lactone form (table 3).

The C bile/C liver of the carboxylate forms of CPT-11, SN-38 and SN38-Glu in SD rats showed obvious saturation when the dose was increased from 10 mg/kg to 40 mg/kg; on the other hand, this was not the case for the lactone forms (tables 1, 2 and 3). In addition, theC bile/C liver of the carboxylate forms of CPT-11, SN-38 and SN38-Glu and the lactone form of SN38-Glu in EHBR at a dose of 10 mg/kg was significantly lower than that in SD rats (tables 1, 2 and 3).

Urinary excretion of CPT-11 and its metabolites.

Nonlinearity was observed in the CL r of the carboxylate forms of CPT-11, SN-38 and SN38-Glu only in SD rats, whereas no clear saturation in the CL r could be observed for those compounds in EHBR. In addition, the lactone forms of CPT-11, SN-38 and SN38-Glu showed a minimal reduction inCL r with increasing dose in both SD rats and EHBR (tables 1, 2 and 3).

Characterization of CMV.

The Mg++-ATPase enrichment factor was 67.6 ± 9.1 (mean ± S.E.,n = 3) and 72.7 (mean value, n = 2) in CMV from SD rats and EHBR, respectively, compared with the corresponding activity in liver homogenate. The alkaline phosphatase enrichment factor was 80.9 ± 7.8 (mean ± S.E.,n = 3) and 76.4 (mean value, n = 2) in SD rats and EHBR, respectively. The ATP-dependent uptake of [3H]taurocholate was 186 ± 2 and 153 ± 10 pmol/2 min/mg protein (mean ± S.E. of three different experiments) and that of [3H]DNP-SG was 178 ± 19 and 0.1 pmol/2 min/mg protein in SD rats and EHBR, respectively.

Study of uptake of CPT-11 and its metabolites by CMV from SD rats and EHBR.

The uptake by CMV from SD rats was markedly stimulated by ATP for the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38 (fig. 7). The uptake showed linearity over at least 2 min. No ATP-dependence was found in the uptake of the lactone form of CPT-11. Due to the low solubility of the lactone form of SN-38 and the detection limit for SN-38 (approximately 0.01 pmol), uptake of the lactone form of SN-38 could not be determined. The uptake by CMV prepared from EHBR was also examined (fig. 8). Compared with SD rats, the ATP-dependent uptake by CMV from EHBR was greatly impaired in the case of the lactone and carboxylate forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38. A minimal ATP-dependence was found for the uptake of the lactone form of CPT-11 by CMV from EHBR.

Figure 7
Figure 7

ATP-dependent uptake of the lactone and carboxylate forms of CPT-11 and its metabolites by CMV obtained from SD rats. CMV were incubated in the presence of ligand (50 μM) with (▪) or without (□) ATP (5 mM) and an ATP-regenerating system. Data are means ± S.E. of three preparations. A, lactone form of SN38-Glu; B, carboxylate form of SN38-Glu; C, lactone form of CPT-11; D, carboxylate form of CPT-11; E, carboxylate form of SN-38.

Figure 8
Figure 8

ATP-dependent uptake of the lactone and carboxylate forms of CPT-11 and its metabolites by CMV obtained from SD rats (A) and EHBR (B). CMV were incubated in the presence of substrate (50 μM) with (▪) or without (□) ATP (5 mM) and an ATP-regenerating system. The uptake time was 2 min. ░, ATP-dependent uptake for each compound. Data are means ± S.E. of three preparations. *P < .05, **P < .01 for the difference in uptake between SD rats and EHBR, by Dunnett’s test.

Effect of the lactone and carboxylate forms of CPT-11 and its metabolites on the uptake of [3H]DNP-SG by CMV from SD rats.

The effects of the lactone and carboxylate forms of CPT-11 and its metabolites on the ATP-dependent uptake of [3H]DNP-SG are shown in figure 9. DNP-SG uptake was significantly inhibited by the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of SN-38 and CPT-11, whereas the lactone form of CPT-11 had little effect on the uptake of DNP-SG (fig. 9). The K i values were 1.03 ± 0.05, 1.62 ± 0.05, 18.3 ± 3.6 and 96.6 ± 8.4 μM for the carboxylate form of SN38-Glu, the lactone form of SN38-Glu and the carboxylate forms of SN-38 and CPT-11, respectively.

Figure 9
Figure 9

Effect of the carboxylate and lactone forms of CPT-11 and its metabolites on ATP-dependent uptake of [3H]DNP-SG (1 μM) by CMV obtained from SD rats. Data are means ± S.E. of three preparations. □, lactone form of CPT-11; ▪, carboxylate form of CPT-11 (K i= 96.6 ± 8.4 μM); ○, carboxylate form of SN-38 (K i = 18.3 ± 3.6 μM); •, carboxylate form of SN38-Glu (K i = 1.03 ± 0.05 μM); ▴, lactone form of SN38-Glu (K i = 1.62 ± 0.05 μM).

Discussion

Although CPT-11 is a potent and novel anticancer drug, a severe side effect (diarrhea) has been observed in some patients during its clinical use. To understand the mechanism for this side effect, it is important to clarify the pharmacokinetics of CPT-11. The pharmacokinetics of CPT-11 in both humans and animals have been widely studied (Ohe et al., 1992; Rothenberg et al., 1993). Nonlinear pharmacokinetics of CPT-11 in rats were previously reported (Kaneda and Yokokura, 1990; Atsumi et al., 1991), showing that CPT-11 and its metabolites recovered from bile during the first 24 hr after drug administration accounted for about 50 to 60% of total drug disposition. Those data suggested that the elimination of CPT-11 and its metabolites in rats is mainly via biliary excretion. However, the biliary excretion mechanism of CPT-11 and its metabolites was unknown. In addition, most previous studies measured only total (sum of carboxylate and lactone forms) concentrations of CPT-11 and its metabolites, rather than considering the biliary excretion of the individual carboxylate and lactone forms of CPT-11 and its metabolites. In this study, we systematically examined the biliary excretion of the carboxylate and lactone forms of CPT-11 and its metabolites in normal rats and EHBR, to clarify the biliary excretion mechanism involved.

The biliary excretion mechanism for the carboxylate and lactone forms of CPT-11, SN-38 and SN38-Glu was investigated in both in vivo and in vitro CMV studies. Because the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38 have anionic charges, we hypothesized that the biliary excretion of these four compounds is mediated by cMOAT, which is known to be genetically deficient in EHBR. The observed results strongly support the validity of our hypothesis. First, in SD rats, theCL bile,h values of the carboxylate forms of CPT-11, SN-38 and SN38-Glu showed obvious saturation when the dose was increased from 10 mg/kg to 40 mg/kg. Second, compared with SD rats, theCL bile,h for the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38 in EHBR were markedly reduced, especially at the lower dose (10 mg/kg). Similarly toCL bile,h, theC bile/C liver showed obvious saturation for the carboxylate forms of CPT-11, SN-38 and SN38-Glu in SD rats (tables 1, 2 and 3). TheC bile/C liver for these three compounds and the lactone form of SN38-Glu in EHBR at a dose of 10 mg/kg was significantly lower than in SD rats. These results suggest that the biliary excretion of these four compounds is by carrier-mediated transport, which is deficient in EHBR. To examine our hypothesis directly, a study of the uptake of the carboxylate and lactone forms of CPT-11 and its metabolites by CMV isolated from SD rats and EHBR was performed. For the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38, the uptake by CMV in SD rats showed a clear ATP-dependence (fig. 7), whereas the ATP-dependent uptake was much lower in CMV obtained from EHBR (fig. 8). On the other hand, no ATP-dependence was found in the uptake of the lactone form of CPT-11 by CMV obtained from either SD rats or EHBR. These results indicate that there is a primary active transport system on the bile canalicular membrane specific for the four compounds with anionic charges and this transport system is deficient in EHBR. Finally, to add further support to our hypothesis, DNP-SG, which is well known as a representative substrate for cMOAT (Akerboom et al., 1991; Takenaka et al., 1995b; Ballatori and Truong, 1995; Yamazaki et al., 1996), was used to study the inhibition of DNP-SG uptake by these compounds. The results shown in figure 9 show that the uptake of DNP-SG by CMV from SD rats is greatly inhibited by the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38. However, no inhibitory effect was found for the lactone form of CPT-11. This result suggests that the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38 share, at least in part, the same transporter as DNP-SG. This finding, therefore, is consistent with the in vivo results with EHBR. Our in vivo and in vitro results, therefore, demonstrate that the biliary excretion of the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38 are mediated by the cMOAT located on the bile canalicular membrane, which is genetically deficient in EHBR. Comparison of the inhibitory efficiency for DNP-SG uptake by CMV, as shown in figure 9, suggests that both the carboxylate and lactone forms of SN38-Glu have a much higher affinity for the DNP-SG transporter than do the carboxylate forms of SN-38 and CPT-11, because theirK i values were much smaller (<2 μM) than those of the carboxylate forms of SN-38 (20 μM) or CPT-11 (100 μM). In addition, for SN38-Glu, the K i value for its carboxylate form (1.0 μM) was smaller than that for the lactone form (1.6 μM), suggesting that the carboxylate form of SN38-Glu has a relatively higher affinity, compared with its lactone form. A similar finding was also obtained in the in vivo study. With increasing dose, saturation in the CL bile,h for the carboxylate form in SD rats was more obvious than for the lactone form (table 3). That is, the CL bile,h for the carboxylate form of SN38-Glu at 10 mg/kg was much greater than that at 40 mg/kg, whereas the difference in the CL bile,hfor the lactone form between 10 and 40 mg/kg was minimal. This result can be explained if the carboxylate form has a higher affinity (lowK m value) for the transporter than does the lactone form and, therefore, saturation of its biliary excretion can be easily observed. One possible factor in such a postulated difference in affinity is that, compared with the lactone form of SN38-Glu, there are two anionic charges present in the carboxylate form of SN38-Glu, and this might result in the higher affinity for the transporter than is the case with its lactone form.

As shown in figure 8, unlike the lactone and carboxylate forms of CPT-11, the ATP-dependent uptake of both lactone and carboxylate forms of SN38-Glu was partially retained in CMV from EHBR at a substrate concentration of 50 μM (fig. 8B). This suggests that a primary active transport system, other than the cMOAT deficient in EHBR, is expressed on the bile canalicular membrane in EHBR. Recently, we found that the ATP-dependent uptake of E3040 glucuronide could also be observed in CMV from EHBR (Niinuma, O. Takenaka, T. Horie, K. Kubayashi, Y. Kato, H. Suzuki and Y. Sugiyama, unpublished observations). Thus, it is possible that multiple transport systems for organic anions are located on the canalicular membrane. In addition, the K i values obtained by evaluating the inhibitory effects of CPT-11 and its metabolites on the ATP-dependent uptake of DNP-SG were 1.0 and 1.6 μM for the carboxylate and lactone forms of SN38-Glu, respectively (fig.9). On the other hand, ATP-dependence was clearly observed in the uptake of both the carboxylate and lactone forms of SN38-Glu at a substrate concentration of 50 μM (figs. 7 and 8). If these compounds share the same transporter (cMOAT) with DNP-SG, their own uptake by CMV at a concentration of 50 μM should be almost saturated and no clear ATP-dependent uptake should be observed. Accordingly, we suggest that there is a multiplicity of biliary excretion systems for both the lactone and carboxylate forms of SN38-Glu on the bile canalicular membrane. A primary active transporter, other than cMOAT, which is still maintained in EHBR, may be responsible for the residual ATP-dependent uptake of these compounds.

The CMV uptake of the carboxylate form of SN-38 also showed ATP-dependence in EHBR. Although the uptake in the presence of ATP (705 ± 31 pmol/mg protein) was significantly higher than the uptake in its absence (523 ± 49 pmol/mg protein), it is still possible that the primary active transporter for SN-38 (carboxylate form) might also be expressed on the bile canalicular membrane in EHBR, because such a difference in CMV uptake in the presence or absence of ATP was not so obvious (fig. 8B), nor was there any significant difference in uptake over 0.5 min in the presence or absence of ATP (data not shown). In addition, when the concentration-dependence of SN-38 uptake by CMV prepared from SD rats was examined, only a single component for the saturation of uptake was found (X.-Y. Chu, Y. Kato and Y. Sugiyama, unpublished observations). Therefore, it is likely that SN-38 (carboxylate form) is recognized only by cMOAT and the contribution of the other transporter is minor.

It has been reported that the diarrhea induced by CPT-11 also occurs in rats and is similar in nature to that in humans (Takasuna et al., 1995a,b). The possible mechanisms for the diarrhea caused by CPT-11 have received a great deal of attention. The diarrhea induced by enterocolitis has been suggested to be caused by high levels of SN-38 and/or CPT-11 retained for a long period in the intestine (Arakiet al., 1993), and the biliary excretion of SN38-Glu may be contributory (Kaneda et al., 1990). One treatment approach based on this hypothesis would be to reduce the intestinal concentration of SN-38 by inhibiting the activity of β-glucuronidase in the intestinal microflora, and baicalin, an inhibitor of β-glucuronidase, has been reported to ameliorate CPT-11-induced diarrhea in rats (Takasuna et al., 1995b). A biliary index (the product of the relative area ratio of SN-38 to SN38-Glu multiplied by that of CPT-11 under the plasma concentration-time curve) has been defined and found to be correlated with the degree of diarrhea in humans (Gupta et al., 1994). This study is in agreement with our hypothesis if we consider that lowering the biliary excretion clearance of SN38-Glu consequently reduces the biliary index; however, we should consider the possibility that interpatient variance in glucuronidation activity might also affect the biliary index and side effects. Our study gives deeper insight into the biliary excretion mechanism of CPT-11 and its metabolites and also suggests that the biliary excretion of SN38-Glu is mediated by cMOAT; therefore, inhibitors of cMOAT may be candidates for ameliorating CPT-11-induced diarrhea. However, the mechanism for the diarrhea caused by CPT-11 is a complicated one. In addition to the possible mechanism discussed, there are other pathways that may also contribute to the diarrheal side effect. Indeed, the intestinal secretion of CPT-11 in rats has been observed (Kaneda and Yokokura, 1990). On the other hand, a recent study in two patients found that the total cumulative biliary and urine excretion of CPT-11 and its metabolites up to 48 hr ranged from 25 to 50% (Lokiec et al., 1995). It is possible that CPT-11 can be excreted by another, as yet unidentified, secretion pathway such as intestinal secretion or eliminated by conversion into other, as yet unidentified, metabolites in humans (Rivory and Robert, 1995). Therefore, it is possible that several other mechanisms may also be involved in the induction of the diarrheal side effect of CPT-11. As for the validity of our hypothesis and whether the mechanism for the toxicity of CPT-11 in rats is similar to that in humans, further investigation is needed. In conclusion, the excretion of the carboxylate and lactone forms of SN38-Glu and the carboxylate forms of CPT-11 and SN-38 across the bile canalicular membrane is mediated by the primary active transporter (cMOAT), which is deficient in EHBR.

Acknowledgments

We are grateful to the Yakult Honsha Co. Ltd. (Tokyo, Japan) for providing CPT-11, SN-38 and SN38-Glu.

Footnotes

  • Send reprint requests to: Dr. Yuichi Sugiyama, Faculty of Pharmaceutical Sciences, University of Tokyo, 7–3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan.

  • ↵1 This study was supported in part by a Grant-in-Aid for Scientific Research provided by the Ministry of Education, Science and Culture of Japan.

  • Abbreviations:
    AUC
    area under the curve
    Cbile/Cliver
    bile-to-liver concentration ratio
    CLbile,h
    biliary excretion clearance defined with respect to the hepatic concentration of the drug
    CLbile,p
    biliary excretion clearance defined with respect to the plasma concentration of the drug
    CLr
    urinary excretion clearance
    cMOAT
    canalicular multispecific organic anion transporter
    CMV
    canalicular membrane vesicle(s)
    CPT
    camptothecin
    CPT-11
    7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin
    DNP-SG
    S-(2,4-dinitrophenyl) glutathione
    EHBR
    Eisai hyperbilirubinemic rat(s)
    HPLC
    high-performance liquid chromatography
    SD
    Sprague-Dawley
    SN38-Glu
    SN-38 glucuronide
    • Received May 10, 1996.
    • Accepted December 6, 1996.

References

  1. ↵
    1. Akerboom T. P. M.,
    2. Narayanaswami V.,
    3. Kunst M.,
    4. Sies H.
    (1991) ATP-dependent S-(2,4-dinitrophenyl) glutathione transport in canalicular plasma membrane vesicles from rat liver. J. Biol. Chem. 266:13147–13152.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Araki E.,
    2. Ishikawa M.,
    3. Iigo M.,
    4. Koide T.,
    5. Itabashi M.,
    6. Hoshi A.
    (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84:697–702.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Atsumi R.,
    2. Suzuki W.,
    3. Hakusui H.
    (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159–1169.
    OpenUrlPubMed
  4. ↵
    1. Ballatori N.,
    2. Truong A. T.
    (1995) Multiple canalicular transport mechanisms for glutathione S-conjugates J. Biol. Chem. 270:3594–3601.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Burke T. G.,
    2. Mi Z.
    (1994) The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J. Med. Chem. 37:40–46.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Fassberg J.,
    2. Stella V. J.
    (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81:676–684.
    OpenUrlPubMed
  7. ↵
    1. Fernandez-Checa J. C.,
    2. Takikawa H.,
    3. Horie T.,
    4. Ookhtens M.,
    5. Kaplowitz N.
    (1992) Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. J. Biol. Chem. 267:1667–1673.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Gupta E.,
    2. Lestingi T. M.,
    3. Mick R.,
    4. Ramirez J.,
    5. Vokes E. E.,
    6. Ratain M. J.
    (1994) Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54:3723–3725.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hertzberg R. P.,
    2. Caranfa M. J.,
    3. Holden K. G.,
    4. Jakas D. R.,
    5. Gallagher G.,
    6. Mattern M. R.,
    7. Mong S. M.,
    8. Bartus J. O.,
    9. Johnson R. K.,
    10. Kingsbury W. D.
    (1989) Modification of the hydroxyl lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32:715–720.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ishikawa T.,
    2. Muller M.,
    3. Klunemann C.,
    4. Schaub T.,
    5. Keppler D.
    (1990) ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane J. Biol. Chem. 265:19279–19286.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kaneda N.,
    2. Nagata H.,
    3. Furuta T.,
    4. Yokokura T.
    (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50:1715–1720.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kaneda N.,
    2. Yokokura T.
    (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50:1721–1725.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kawato Y.,
    2. Aonuma M.,
    3. Hirota Y.,
    4. Kuga H.,
    5. Sato K.
    (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:4187–4191.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Kim R.,
    2. Hirabayashi N.,
    3. Nishiyama M.,
    4. Jinushi K.,
    5. Toge T.,
    6. Okada K.
    (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer 50:760–766.
    OpenUrlPubMed
  15. ↵
    1. Kobayashi K.,
    2. Sogame Y.,
    3. Hara H.,
    4. Hayashi K.
    (1990) Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J. Biol. Chem. 265:7737–7741.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kojima A.,
    2. Shinkai T.,
    3. Saijo N.
    (1993) Cytogenetic effects of CPT-11 and its active metabolite, SN-38, on human lymphocytes. Jpn. J. Clin. Oncol. 23:116–122.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Lokiec F.,
    2. Canal P.,
    3. Gay C.,
    4. Chatelut E.,
    5. Armand J. P.,
    6. Roche H.,
    7. Bugat R.,
    8. Goncalves E.,
    9. Mathicu B. A.
    (1995) Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol. 36:79–82.
    OpenUrlPubMed
  18. ↵
    Miyasaka, T., Mutai, M., Sawada, S., Nokada, K. and Hagiwara, H.: Synthesis of new camptothecin derivatives. Japanese Patent Kokai 56–158786, 1981..
  19. ↵
    1. Nagata H.,
    2. Kaneda N.,
    3. Furuta T.,
    4. Sawada S.,
    5. Yokokura T.,
    6. Miyasaka T.,
    7. Fukuda M.,
    8. Notake K.
    (1987) Action of 7-ethylcampwthecin on tumor cells and its disposition in mice. Cancer Treat. Rep. 71:341–348.
    OpenUrlPubMed
  20. ↵
    1. Negoro S.,
    2. Fukuoka M.,
    3. Masuda N.,
    4. Takada M.,
    5. Kusunoki Y.,
    6. Matsui K.,
    7. Takifuji N.,
    8. Kudoh S.,
    9. Niitani H.,
    10. Taguchi T.
    (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83:1164–1168.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Nishida T.,
    2. Hardenbrook C.,
    3. Gatmaitan Z.,
    4. Arias I. M.
    (1992) ATP-dependent organic anion transport system in normal and TR− rat liver canalicular membranes. Am. J. Physiol. 258:G629–G635.
    OpenUrl
  22. ↵
    1. Ohe Y.,
    2. Sasaki Y.,
    3. Shinkai T.,
    4. Eguchi K.,
    5. Tamura T.,
    6. Kojima A.,
    7. Kunikane H.,
    8. Okamoto H.,
    9. Karato A.,
    10. Ohmatsu H.,
    11. Kanzawa F.,
    12. Saijo N.
    (1992) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84:972–974.
    OpenUrlFREE Full Text
  23. ↵
    1. Ohno R.,
    2. Okada K.,
    3. Masaoka T.,
    4. Kuramoto A.,
    5. Arima T.,
    6. Yoshida Y.,
    7. Ariyoshi H.,
    8. Ishimaru M.,
    9. Sakai Y.,
    10. Oguro M.,
    11. Ito Y.,
    12. Morishima Y.,
    13. Yokomaku S.,
    14. Ota K.
    (1990) An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1907–1912.
    OpenUrlAbstract
  24. ↵
    1. Pikula S.,
    2. Hayden J. B.,
    3. Awasthi S.,
    4. Awasthi Y. C.,
    5. Zimniak P.
    (1994) Organic anion-transporting ATPase of rat liver. J. Biol. Chem. 269:27566–27573.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Rivory L. P.,
    2. Robert J.
    (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolites SN-38 in plasma. J. Chromatogr. B 661:133–141.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Rivory L. P.,
    2. Robert J.
    (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother. Pharmacol. 36:176–179.
    OpenUrlPubMed
  27. ↵
    1. Rothenberg M. L.,
    2. Kuhn J. G.,
    3. Burris H. A., III,
    4. Nelson J.,
    5. Eckardt J. R.,
    6. Tristan-Morales M.,
    7. Hilsenbeck S. G.,
    8. Weiss G. R.,
    9. Smith L. S.,
    10. Rodriguez G. I.,
    11. Rock M. K.,
    12. Von Hoff D. D.
    (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11:2194–2204.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Rowinsky E. K.,
    2. Grochow L. B.,
    3. Ettinger D. S.,
    4. Sartorius S. E.,
    5. Lubejko B. G.,
    6. Chen T. L.,
    7. Rock M. K.,
    8. Donehower R. C.
    (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54:427–436.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Sasaki Y.,
    2. Hakusui H.,
    3. Mizuno S.,
    4. Morita M.,
    5. Miya T.,
    6. Eguchi K.,
    7. Shinkai T.,
    8. Tamura T.,
    9. Ohe Y.,
    10. Saijo N.
    (1995a) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res. 86:101–110.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Sasaki Y.,
    2. Yoshida Y.,
    3. Sudoh K.,
    4. Hakusui H.,
    5. Fujii H.,
    6. Ohtsu T.,
    7. Wakita H.,
    8. Igarashi T.,
    9. Itoh K.
    (1995b) Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer Res. 86:111–116.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Sathirakul K.,
    2. Suzuki H.,
    3. Yamada T.,
    4. Hanano M.,
    5. Sugiyama Y.
    (1994) Multiple transport systems for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 268:65–73.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sathirakul K.,
    2. Suzuki H.,
    3. Yasuda K.,
    4. Hanano M.,
    5. Tageya O.,
    6. Horie T.,
    7. Sugiyama Y.
    (1993) Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats J. Pharmacol. Exp. Ther. 265:1301–1312.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Scharschmidt B.F.,
    2. Keefe E.B.,
    3. Blankenship N.M.,
    4. Ockner R.K.
    (1979) Validation of a recording spectrophotometric method for measurement of membrane-associated Mg++ and Na+/K+-ATPase activity. J. Lab. Clin. Med. 93:790–799.
    OpenUrlPubMed
  34. ↵
    1. Shimamura H.,
    2. Suzuki H.,
    3. Hanano M.,
    4. Suzuki A.,
    5. Tageya O.,
    6. Horie T.,
    7. Sugiyama Y.
    (1994) Multiple systems for the biliary excretion of organic anions in rats: Liquiritigenin conjugates as model compounds. J. Pharmacol. Exp. Ther. 271:370–378.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Slichenmyer W. J.,
    2. Rowinsky E. K.,
    3. Donehower R. C.,
    4. Kaufmann S. H.
    (1993) The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:271–291.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Takasuna K.,
    2. Kasai Y.,
    3. Kitano Y.,
    4. Mori K.,
    5. Kakihata K.,
    6. Hirohashi M.,
    7. Nomura M.
    (1995a) Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol. Jpn. 105:447–460.
    OpenUrl
  37. ↵
    1. Takasuna K.,
    2. Kasai Y.,
    3. Kitano Y.,
    4. Mori K.,
    5. Kobayashi R.,
    6. Hagiwara T.,
    7. Kakihata K.,
    8. Hirohashi M.,
    9. Nomura M.,
    10. Nagai E.,
    11. Kamataki T.
    (1995b) Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res. 86:978–984.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Takenaka O.,
    2. Horie T.,
    3. Suzuki H.,
    4. Sugiyama Y.
    (1995a) Different biliary excretion systems for glucuronide and sulfate of a model compound: Study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther. 274:1362–1369.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Takenaka O.,
    2. Horie T.,
    3. Kobayashi K.,
    4. Suzuki H.,
    5. Sugiyama Y.
    (1995b) Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. 12:1746–1755.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Tanizawa A.,
    2. Fujimori A.,
    3. Fujimori Y.,
    4. Pommier Y.
    (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. 86:836–842.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Yachi K.,
    2. Sugiyama Y.,
    3. Sawada Y.,
    4. Iga T.,
    5. Ikeda Y.,
    6. Toda G.,
    7. Hanano M.
    (1989) Characterization of rose bengal binding to sinusoidal and canalicular plasma membrane from rat liver. Biochim. Biophys. Acta 978:1–7.
    OpenUrlPubMed
  42. ↵
    1. Yamazaki M.,
    2. Suzuki H.,
    3. Sugiyama Y.
    (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13:497–513.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
OtherDRUG METABOLISM AND DISPOSITION

Multispecific Organic Anion Transporter Is Responsible for the Biliary Excretion of the Camptothecin Derivative Irinotecan and its Metabolites in Rats

Xiao-Yan Chu, Yukio Kato, Kayoko Niinuma, Ken-Ichi Sudo, Hideo Hakusui and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics April 1, 1997, 281 (1) 304-314;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section